Rhumbline Advisers Ngm Biopharmaceuticals Inc Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$1.17 - $1.92 $1,729 - $2,837	1,478 Added 2.28%	66,344 $105,000
Q3 2023 Nov 09, 2023	BUY	$1.05 - $3.37 $2,951 - $9,473	2,811 Added 4.53%	64,866 $69,000
Q2 2023 Aug 08, 2023	BUY	$2.44 - $4.53 $15,525 - $28,824	6,363 Added 11.43%	62,055 $160,000
Q1 2023 May 11, 2023	BUY	$3.72 - $5.4 $3,664 - $5,319	985 Added 1.8%	55,692 $227,000
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $1,844 - $6,995	541 Added 1.0%	54,707 $275,000
Q3 2022 Nov 10, 2022	BUY	$12.59 - $17.67 $53,494 - $75,079	4,249 Added 8.51%	54,166 $708,000
Q2 2022 Aug 11, 2022	BUY	$10.58 - $17.5 $106,974 - $176,942	10,111 Added 25.4%	49,917 $640,000
Q1 2022 May 12, 2022	SELL	$13.81 - $18.6 $37,563 - $50,592	-2,720 Reduced 6.4%	39,806 $607,000
Q4 2021 Feb 10, 2022	SELL	$17.26 - $22.02 $7,093 - $9,050	-411 Reduced 0.96%	42,526 $753,000
Q3 2021 Nov 12, 2021	BUY	$20.15 - $26.19 $42,456 - $55,182	2,107 Added 5.16%	42,937 $903,000
Q2 2021 Aug 05, 2021	BUY	$15.06 - $30.03 $185,810 - $370,510	12,338 Added 43.3%	40,830 $805,000
Q1 2021 May 06, 2021	SELL	$24.99 - $31.93 $21,491 - $27,459	-860 Reduced 2.93%	28,492 $828,000
Q4 2020 Feb 10, 2021	BUY	$16.21 - $31.44 $30,426 - $59,012	1,877 Added 6.83%	29,352 $889,000
Q3 2020 Nov 12, 2020	SELL	$15.59 - $19.97 $64,168 - $82,196	-4,116 Reduced 13.03%	27,475 $437,000
Q2 2020 Aug 13, 2020	BUY	$11.97 - $23.47 $62,196 - $121,950	5,196 Added 19.69%	31,591 $624,000
Q1 2020 May 06, 2020	BUY	$10.0 - $19.51 $29,390 - $57,339	2,939 Added 12.53%	26,395 $325,000
Q4 2019 Feb 05, 2020	BUY	$9.97 - $20.28 $233,856 - $475,687	23,456 New	23,456 $434,000

Others Institutions Holding NGM

# of Institutions

Shares Held

2.6M

Call Options Held

300

Put Options Held

View Full List

About NGM BIOPHARMACEUTICALS INC

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

More about NGM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account